GPR119 agonists: A promising new approach for the treatment of type 2 diabetes and related metabolic disorders

Current Opinion in Drug Discovery and Development

Volumn 12, Issue 4, 2009, Pages 519-532

  Shah, Unmesh ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Agonist; Antidiabetic agent; GLP 1; GPCR; GPR119; Obesity; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; APD 597; APD 668; AR 231453; CYCLIC AMP; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 119; G PROTEIN COUPLED RECEPTOR 119 AGONIST; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LYSOPHOSPHATIDYLCHOLINE; MBX 2982; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PSN 119 1; PSN 119 1M; PSN 119 2; PSN 375963; PSN 632408; PSN 821; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; SITAGLIPTIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TARGETING; EDEMA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEART FAILURE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS; PANCREATITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIDE EFFECT; STRUCTURE ANALYSIS; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC DISEASES; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; SMALL MOLECULE LIBRARIES;

EID: 67649979936     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (107)

1. Diabetes fact sheet 312: WHO, Geneva, Switzerland (2008). www.who.int/mediacentre/factsheets/fs312/en/index.html
2. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047-1053.
3. Diamond J: The double puzzle of diabetes. Nature (2003) 423(6940):599-602.
4. Hossain P, Kawar B, El Nahas M: Perspective: Obesity and diabetes in the developing world - A growing challenge. N Engl J Med(2007) 356(3):213-215.
5. Leahy JL: Pathogenesis of type 2 diabetes mellitus. In: Type 2 Diabetes Mellitus: An Evidence-Based Approach to Practical Management. Feinglos MN, Angelyn Bethel M (Eds), Humana Press, NJ, USA (2008):17-33.
6. Skyler JS: Diabetes mellitus: Pathogenesis and treatment strategies. J Med Chem (2004) 47(17):4113-4117.
7. Goldberg RB, Holman R, Drucker DJ: Management of type 2 diabetes. N Engl J Med (2008) 358(3):293-297.
8. Levetan C: Oral antidiabetic agents in type 2 diabetes.Curr Med Res Opin (2007) 23(4):945-952.
9. Ashiya M, Smith RET: Non-insulin therapies for type 2 diabetes.Nat Rev Drug Discov (2007) 6(10):777-778.
10. Bailey CJ, Turner RC: Metformin. N Engl J Med (1996) 334(9):574- 579.
11. Bailey CJ: Metformin: Effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther (2008) 22(3):215-224.
12. Howlett HCS, Bailey CJ: A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf (1999) 20(6): 489-503.
13. Yki-Järvinen H: Thiazolidinediones. N Engl J Med (2004) 351(11):1106-1118.
14. Staels B, Fruchart JC: Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 54(8):2460-2470.
15. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH et al: Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation(2003) 108(23):2941-2948.
16. Nissen SE, Woslki K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.N Engl J Med (2007) 356(24):2457-2471.
17. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: A nested case-control analysis. Diabetes Care (2008) 31(11):2086-2091.
18. Blickle JF: Meglitinide analogues: A review of clinical data focused on recent trials. Diabetes Metab (2006) 32(2):113-120.
19. Godbout A, Chiasson JL: Who should benefit from the use ofα-glucosidase inhibitors? Curr Diab Rep (2007) 7(5):333-339.
20. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC, 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med(2007) 357(17):1716- 1730.
21. Gutniak M, Orskov C, Holst JJ, Ahrén B, Efendic S: Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med (1992) 326(20):1316-1322.
22. Drucker DJ, Nauck MA: The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 368(9548): 1696-1705.
23. Baggio LL, Drucker DJ: Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med (2006) 57:265-281.
24. Brubaker PL, Drucker DJ: Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology (2004) 145(6):2653-2659.
25. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagonlike peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.Endocrinology (2003) 144(12):5149-5158.
26. Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucosedependent insulinotropic polypeptide and truncated glucagonlike peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 136(8):3585-3596.
27. Information for healthcare professionals - Exenatide (marketed as Byetta): Food and Drug Administration, Silver Springs, MD, USA (2008). www.fda.gov/cder/drug/InfoSheets/HCP/ exenatide2008HCP.htm
28. Brubaker PL: Incretin-based therapies: Mimetics versus protease inhibitors. Trends Endocrinol Metab (2007) 18(6): 240-245.
29. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB: Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes (2007) 56(1):8-15.
30. Fyfe MCT, Overton HA, Procter MJ, Reynet C, White JR: New nonpeptide-binding GPCRs as targets for diabetes and the metabolic syndrome. Annu Rep Med Chem (2007) 42:129-145. · Summarizes several of the emerging non-peptide-GPCR targets including GPR119 for the potential treatment of T2D and related metabolic disorders.
31. Ahrén B: Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes. Nat Rev Drug Discov (2009) 8(5):369-385.
32. Mohler ML, He Y, Wu Z, Hwang DJ, Miller DD: Recent and emerging anti-diabetes targets. Med Res Rev (2009) 29(1):125-195.
33. Fredriksson R, Höglund PJ, Gloriam DE, Lagerström MC, Schiöth HB: Seven evolutionarily conserved human rhodopsin G proteincoupled receptors lacking close relatives. FEBS Lett (2003) 554(3):381-388.
34. Fyfe MCT, McCormack JG, Overton HA, Procter MJ, Reynet C: GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity. Expert Opin Drug Discov(2008) 3(4):403-413. ·· Recent review summarizing GPR119 biology and data on several of the early synthetic agonists.
35. Costanzi S, Neumann S, Gershengorn MC: Seven transmembranespanning receptors for free fatty acids as therapeutic targets for diabetes mellitus: Pharmacological, phylogenetic, and drug discovery aspects. J Biol Chem (2008) 283(24):16269- 16273.
36. Brown AJ: Novel cannabinoid receptors. Br J Pharmacol (2007) 152(5):567-575.
37. Soga T, Ohishi T, Matsui T, Saito T, Matsumoto M, Takasaki J, Matsumoto S, Kamohara M, Hiyama H, Yoshida S, Momose K et al: Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor.Biochem Biophys Res Commun (2005) 326(4):744-751. · The deorphanization of GPR119 with LPC as a potential endogenous ligand was described.
38. Chu ZL, Jones RM, He H, Carroll C, Gutierrez V, Lucman A, Moloney M, Gao H, Mondala H, Bagnol D, Unett D et al: A role forβ-cell- expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.Endocrinology (2007) 148(6):2601-2609. ·· Evidence for the β-cell expression of GPR119 and its role in enhancing glucose-dependent insulin release using their validation tool compound AR-231453 was provided.
39. Sakamoto Y, Inoue H, Kawakami S, Miyawaki K, Miyamoto T, Mizuta K, Itakura M: Expression and distribution of GPR119 in the pancreatic islets of mice and rats: Predominant localization in pancreatic polypeptide-secreting PP-cells.Biochem Biophys Res Commun (2006) 351(2):474-480.
40. Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R et al: A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide release.Endocrinology (2008) 149(5):2038-2047. ·· Describes the intestinal expression of GPR119 and its role in glucose homeostasis by increasing GLP-1 and GIP levels.
41. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F: Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells.Diabetologia (2009) 52(2):289-298.
42. Overton HA, Babbs AJ, Doel SM, Fyfe MC, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS et al: Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab (2006) 3(3):167-175. ·· Describes OEA as a potential endogenous ligand for GPR119 and also provides initial evidence for the role of GPR119 agonists in modulating food-intake and body weight.
43. Ning Y, O'Neill K, Lan H, Pang L, Shan LX, Hawes BE, Hedrick JA: Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. Br J Pharmacol (2008) 155(7):1056- 1065.
44. Rodríguez de Fonseca F, Navarro M, Gómez R, Escuredo L, Nava F, Fu J, Murillo-Rodríguez E, Giuffrida A, LoVerme J, Gaetani S, Kathuria S et al: An anorexic lipid mediator regulated by feeding. Nature (2001) 414(6860):209-212.
45. Lan H, Vassileva G, Corona A, Liu L, Baker H, Golovko A, Abbondanzo SJ, Hu W, Yang S, Ning Y, Del Vecchio RA et al: GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.J Endocrinol (2009) 201(2):219-230.
46. Schwartz GJ, Fu J, Astarita G, Li X, Gaetani S, Campolongo P, Cuomo V, Piomelli D: The lipid messenger OEA links dietary fat intake to satiety. Cell Metab (2008) 8(4):281-288.
47. Lauffer LM, Iakoubov R, Brubaker PL: GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes (2009) 58(5):1058-1066.
48. Kelly E, Bailey CP, Henderson G: Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol (2008) 153(Suppl 1):S379-S388.
49. Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Choi K, Xiong Y, Ren A, Morgan M, Dave V, Thomsen W et al: Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. J Med Chem (2008) 51(17): 5172-5175. · Describes the SAR leading to the discovery of Arena's early lead, AR-231453.
50. Potenza MN, Graminski GF, Lerner MR: A method for evaluating the effects of ligands upon Gs protein-coupled receptors using a recombinant melanophore-based bioassay. Anal Biochem(1992) 206(2):315-322.
51. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B: Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin secreting β-cells.J Biol Chem (1993) 268(26): 19650-19655.
52. Kolligs F, Fehmann HC, Göke R, Göke B: Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes (1995) 44(1):16-19.
53. Drucker DJ: The role of gut hormones in glucose homeostasis.J Clin Invest (2007) 117(1):24-32.
54. Jones RM: Discovery of agonists of the glucose dependent insulinotropic receptor, GPR119, a pancreatic β-cell oGPCR, for the treatment of NIDDM. 232nd American Chemical Society National Meeting, San Francisco, CA, USA (2006):MEDI 275.
55. Fyfe MCT, Babbs AJ, Bertram LS, Bradley SE, Doel SM, Gadher S, Gattrell WT, Jeevaratnam RP, Keily JF, McCormack JG, Overton HA et al: Synthesis, SAR, and in vivo efficacy of novel GPR119 agonists with a 4-[3-(4-methanesulfinylphenoxy)propyl]-1- Boc-piperidine core. American Chemical Society National Meeting, Boston, MA, USA (2007) 234:MEDI 062.
56. Fyfe MCT, Babbs AJ, Bertram LS, Bradley SE, Doel SM, Gadher S, Gattrell WT, Jeevaratnam RP, Keily JF, McCormack JG, Overton HA et al: Discovery of PSN119-2, a novel oxadiazole-containing GPR119 agonist. American Chemical Society National Meeting, Philadelphia, PA, USA (2008) 236:MEDI 197.
57. Arena Pharmaceuticals Inc: Arena Pharmaceuticals, Inc. announces initiation of phase 1 clinical trial of Arena type 2 diabetes drug candidate in collaboration with Ortho-McNeil.Press Release (2006):February 07.
58. Semple G: Discovery and pharmacological evaluation of agonists of the orphan receptor GDIR (GPR119). Second RSCSCI Symposium on GPCRs in Medicinal Chemistry, Gothenburg, Sweden (2008). · Preclinical data on Arena's first clinical candidate APD-668, which was discontinued to advance a more potent GPR119 agonist, were presented.
59. Arena Pharmaceuticals Inc: Arena Pharmaceuticals announces APD668 initial clinical study results suggest glucose-dependent insulinotropic receptors may improve glucose control in patients with type 2 diabetes. Press Release (2008):January 07.
60. Arena Pharmaceuticals Inc: Arena Pharmaceuticals announces initiation of phase 1 clinical trial of type 2 diabetes drug candidate in partnership with Ortho-McNeil-Janssen Pharmaceuticals. Press Release (2008):December 15.
61. OSI Pharmaceuticals: OSI Pharmaceuticals initiates clinical development program for anti-diabetes candidate, PSN821.Press Release (2008):September 03.
62. Fyfe M, Mccormack J, Overton H, Procter M, Reynet C: PSN821: A novel oral GPR119 agonist for the treatment of type 2 diabetes producing substantial glucose lowering and weight loss in rats. American Diabetes Association Annual Scientific Sessions, San Francisco, CA, USA (2008) 68:Abs 297-OR. · Provided preclinical data on Prosidion's compound PSN-821, which is currently being evaluated in a phase I clinical trial.
63. OSI Pharmaceuticals: OSI Pharmaceuticals provides update on diabetes and obesity clinical programs. Press Release (2009): May 11.
64. Metabolex Inc: Metabolex announces positive results from phase 1a clinical trial of MBX-2982. Press Release (2008): November 03.
65. Swain S, Cock TA, Wong-Kai-In P: A novel dual DPP-IV inhibitor and GPR119 agonist that exhibits superior glucose lowering to sitagliptin in diabetic ZDF rats. American Diabetes Association Annual Scientific Sessions, New Orleans, LA, USA (2009) 69:Abs 453-P.
66. Prosidion (Griffin G): Methods for identification of modulators of OSGPR116 activity. US-07083933 (2006).
67. Synaptic Pharmaceutical Corp (Bonini JA, Borowsky BE, Adham N, Boyle N, Thompson TO): DNA encoding SNORF25 receptor.US-06221660 (2001).
68. Arena Pharmaceuticals Inc (Jones RM, Semple G, Fioravanti B, Pereira G, Calderon I, Uy J, Duvvuri K, Choi JSK, Xiong Y, Dave V): 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia. WO-2004065380 (2004).
69. Arena Pharmaceuticals Inc (Chu Z-L, Leonard JN, Al-Shamma HA, Jones RM): Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level.US-20060154866 (2006). · Provides evidence that GPR119 agonism and DPP-IV inhibition in combination lead to significant improvement in glycemic control.
70. (OSI) Prosidion (Fyfe MCT, Widdowson P): Use of GPCR agonists to delay progression of diabetes. WO-2007138362 (2007). · Explains the effects of a Prosidion's GPR119 agonist in delaying the progression of diabetes in animal models.
71. (OSI) Prosidion (Fyfe M, Gardner L, King-Underwood J, Procter M, Rasamison C, Schofield K, Thomas GH): Heterocyclic derivatives as GPCR receptor agonists. WO-2005061489 (2005).
72. Arena Pharmaceuticals Inc (Jones RM, Semple G, Xiong Y, Shin Y-J, Ren AS, Lehmann J, Fioravanti B, Bruce MA, Choi JSK): Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto. WO-2005121121 (2005).
73. Arena Pharmaceuticals Inc (Jones RM, Semple G, Xiong Y, Shin Y-J, Ren AS, Calderon I, Choi JSK, Fioravanti B, Lehmann J, Bruce MA): Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto. WO-2005007647 (2005).
74. Arena Pharmaceuticals Inc (Jones RM, Lehmann J, Wong AS, Hurst D, Shin Y-J): Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto. US-20070167473 (2007).
75. Arena Pharmaceuticals Inc (Gharbaoui T, Fritch JR, Krishnan AM, Throop BW, Kato NS): Processes for preparing aromatic ethers.US-20060155129 (2006).
76. Arena Pharmaceuticals Inc (Jones RM, Lehmann J): Modulators of metabolism and the treatment of disorders related thereto.WO-2007035355 (2007).
77. Arena Pharmaceuticals Inc (Jones RM, Lehmann J, Siu-Ting Wong A): Modulators of metabolism and the treatment of disorders related thereto. WO-2008005569 (2008).
78. Arena Pharmaceuticals Inc (Jones RM, Lehmann J): Modulators of metabolism and the treatment of disorders related thereto.WO-2008005576 (2008).
79. Arena Pharmaceuticals Inc (Jones RM, Semple G, Xiong Y, Shin Y-J, Ren AS, Calderon I, Fioravanti B, Choi JSK, Sage CR): Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto.WO-2005007658 (2005).
80. Arena Pharmaceuticals Inc (Gharbaoui T, Sengupta D, Lally EA, Kato NS, Carlos M, Rodriguez N): Processes for preparing pyrazolo[3,4-d] pyrimidine ethers. US-20060154940 (2006).
81. (OSI) Prosidion (Fyfe MCT, Gardner LS, Thomas GH, Williams GM): G-protein coupled receptor (GPR116) agonists and use thereof for treating obesity and diabetes. WO-2006067531 (2006).
82. (OSI) Prosidion (Bradley SE, Dawson GJ, Fyfe MCT, Bertram LS, Gattrell W, Jeevaratnam RP, Keily J, Mistry NS, Procter MJ, Rasamison CM, Rushworth PJ et al): GPCR agonists. WO-2007003960 (2007).
83. (OSI) Prosidion (Bertram LS, Fyfe MCT, Procter MJ, Williams GM): Heterocyclic GPCR agonists. WO-2007116229 (2007).
84. (OSI) Prosidion (Fyfe MCT, Keily J, Swain SA): Piperidine GPCR agonists. WO-2008081204 (2008).
85. (OSI) Prosidion (Fyfe MCT, Jeevaratnam RP, Keily J, Swain SA): Piperidine GPCR agonists. WO-2008081207 (2008).
86. (OSI) Prosidion (Fyfe MCT, Jeevaratnam RP, Keily J, Swain SA): Piperidine GPCR agonists. WO-2008081208 (2008).
87. (OSI) Prosidion (Bertram LS, Fyfe MCT, Jeevaratnam RP, Keily J, Swain SA): Piperidine GPCR agonists. WO-2008081205 (2008).
88. (OSI) Prosidion (Barba O, Bradley SE, Fyfe MCT, Hanrahan PE, Krulle TM, Procter MJ, Reynet Mccormack C, Schofield KL, Smyth D, Stewart AJW, Swain SA et al): Compounds for the treatment of metabolic disorders. WO-2009034388 (2009).
89. Metabolex Inc (Chen X, Cheng P, Clemens LE, Johnson JD, Ma J, Murphy A, Nashashibi I, Rabbat CJ, Song J, Wilson ME, Zhu Y et al): Heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders. WO-2008083238 (2008).
90. Metabolex Inc (Ma J, Rabbat CJ, Song J, Chen X, Nashashibi I, Zhao Z, Novack A, Shi DF, Cheng P, Zhu Y, Murphy A): N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders. WO-2009014910 (2009).
91. Bristol-Myers Squibb Co (Fevig JM, Wacker DA): [6,6] and [6,7]-Bicyclic GPR119 G protein-coupled receptor agonists.WO-2008137435 (2008).
92. Bristol-Myers Squibb Co (Fevig JM, Wacker DA): [6,5]-Bicyclic GPR119 G protein-coupled receptor agonists. WO-2008137436 (2008).
93. Bristol-Myers Squibb Co (Wacker DA, Rossi KA, Wang Y): Pyridone GPR119 G protein-coupled receptor agonists. WO-2009012275 (2009).
94. Bristol-Myers Squibb Co (Wacker DA, Rossi KA, Wang Y): Method for modulating GPR119 G protein-coupled receptor and selected compounds. WO-2009012277 (2009).
95. Smithkline Beecham Corp (Katamreddy SR, Caldwell RD, Heyer D, Samano V, Thompson JB, Carpenter AJ, Conlee CR, Boros EE, Thompson BD): Chemical compounds. WO-2008008887 (2008).
96. Smithkline Beecham Corp (Ammala C, Briscoe C): GPR119 agonists for the treatment of diabetes and related disorders.WO-2008008895 (2008).
97. Smithkline Beecham Corp (Fang J, Tang J, Carpenter AJ, Peckham G, Conlee CR, Du KS, Katamreddy SR): Chemical compounds and uses. WO-2008070692 (2008).
98. Biovitrum AB (Brandt P, Emond R, Johansson G, Johansson L, Koolmeister T, Nilsson BM, Sandvall T, Weber M): Pyridine compounds for treating GPR119 related disorders.WO-2008025798 (2008).
99. Biovitrum AB (Brandt P, Johansson G, Johansson L, Koolmeister T, Nilsson BM, Sandvall T): Pyridazine compounds for treating GPR119 related disorders. WO-2008025799 (2008).
100. Biovitrum AB (Brandt P, Johansson G, Johansson L, Koolmeister T, Nilsson BM, Sandvall T, Weber M): Pyrimidine compounds for treating GPR119 related disorders. WO-2008025800 (2008).
101. Schering Corp (Boyle CD, Neelamkavil SF, Chackalamannil S, Neustadt BR, Hao J, Shah U, Harris J, Liu H, Stamford AW): Pyrimidinone derivatives and methods of use thereof.WO-2008130581 (2008).
102. Schering Corp (Boyle CD, Chackalamannil S, Lankin CM, Shah UG, Neustadt BR, Liu H, Stamford AW): Pyrimidinone derivatives and methods of use thereof. WO-2008130584 (2008).
103. Merck & Co Inc (Wood HB, Adams AD, Freeman S, Szewczyk JW, Santini C, Huang Y, Mosley RT): Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment. WO-2008076243 (2008).
104. Merck & Co Inc (Wood HB, Adams AD, Freeman S, Szewczyk JW, Santini C, Huang Y): Bipiperidinyl compounds, compositions containing such compounds and methods of treatment.WO-2008085316 (2008).
105. IRM LLC (Alper P, Azimioara M, Cow C, Epple R, Jiang S, Lelais G, Michellys P-Y, Nguyen TN, Westscott-Baker L, Wu B): Compounds and compositions as modulators of GPR119 activity.WO-2008097428 (2008).
106. IRM LLC (Alper PB, Lelais G, Epple R, Mutnick D): Compounds and compositions as modulators of GPR119 activity. WO-2008109702 (2008).
107. IRM LLC (Alper P, Azimioara M, Cow C, Epple R, Jiang S, Lelais G, Michellys P-Y, Mutnick D, Nikulin V, Westcott-Baker L): Compounds and compositions as modulators of GPR119 activity.WO-2009038974 (2009).